Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

March 23, 2006

Primary Completion Date

July 28, 2008

Study Completion Date

August 1, 2011

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

bevacizumab

DRUG

capecitabine

DRUG

fluorouracil

DRUG

irinotecan hydrochloride

DRUG

leucovorin calcium

Trial Locations (15)

13273

Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille

14076

Centre Regional Francois Baclesse, Caen

21079

Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon

24004

Polyclinique Francheville, Périgueux

29200

C.H.U. de Brest, Brest

33310

Polyclinique des Quatre Pavillons, Lormont

34298

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier

35062

Centre Eugene Marquis, Rennes

51056

Institut Jean Godinot, Reims

54511

Centre Alexis Vautrin, Vandœuvre-lès-Nancy

59020

Centre Oscar Lambret, Lille

75248

Institut Curie Hopital, Paris

92210

Centre Rene Huguenin, Saint-Cloud

06189

Centre Antoine Lacassagne, Nice

F-94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

UNICANCER

OTHER

NCT00423696 - Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter